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Data originating from biomedical experiments has provided machine learning researchers with an important source of motiva-
tion for developing and evaluating new algorithms. A new wave of algorithmic development has been initiated with the publication
of gene expression data derived from microarrays. Microarray data analysis is particularly challenging given the large number of
measurements (typically in the order of thousands) that are reported for relatively few samples (typically in the order of dozens).
Many data sets are now available on the web. It is important that machine learning researchers understand how data are obtained
and which assumptions are necessary in the analysis. Microarray data have the potential to cause signiﬁcant impact in machine
learning research, not just as a rich and realistic source of cases for testing new algorithms, as has been the UCI machine learning
repository in the past decades, but also as a main motivation for their development. In this article, we brieﬂy review the biology
underlying microarrays, the process of obtaining gene expression measurements, and the rationale behind the common types of
analyses involved in a microarray experiment. We outline the main challenges and reiterate critical considerations regarding the con-
struction of supervised learning models that use this type of data. The goal of this article is to familiarize machine learning research-
ers with data originated from gene expression microarrays.
 2004 Elevier Inc. All rights reserved.
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Understanding the inter-cellular and intra-cellular
processes underlying many diseases is essential for
improving the capacity to diagnose and treat patients.
Unraveling the complexity underlying these biological
processes is expected to provide novel predictive tools
to enable, for example, the sub-classiﬁcation of diseases1532-0464/$ - see front matter  2004 Elevier Inc. All rights reserved.
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machado@dsg.harvard.edu (L. Ohno-Machado).and eventual identiﬁcation of proper therapeutic drug
targets. The potential for further characterization of reg-
ulatory networks and pathways controlling the cellular
homeostasis that are altered in diseases has been seen
as one of the main promises of global analyses of gene
expression proﬁles. Microarrays that measure the
expression of thousands of genes simultaneously have
been perceived by many as a ﬁrst step towards this ambi-
tious goal [1–4].
Biomedical researchers are trying to discover rela-
tionships between genes and disease or developmental
stages, as well as relationships among genes. For
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discovery of novel biomarkers for cancer, which can
provide more accurate diagnosis and monitoring tools
for early detection of a particular subtype of disease or
assessment of eﬀectiveness of a particular treatment pro-
tocol. Since microarray experiments have been growing
in terms of usage across laboratories, the amount of
data is rapidly growing, thus creating an environment
for new computational strategies.
1.1. A new type of data
The availability of public repositories of data that are
suitable for machine learning research is extremely
important to the ﬁeld of biomedical informatics. The
UCI machine learning repository (http://www.ics.uci.
edu/~mlearn/MLRepository.html), which contains clini-
cal and biological datasets, has allowed a large number
of researchers to demonstrate the performance of new
statistical and machine learning algorithms in the past
two decades. New centralized (http://www.ncbi.nlm.
nih.gov/geo/) and decentralized sources of biomedical
data (mostly from supplemental data in journals or
researchers web sites) have started to accumulate since
the advent of high-throughput measurement technolo-
gies such as gene expression microarrays. This new
and free source of data is receiving increasing attention
from researchers in the machine learning community,
and the number of publications is increasing at a rapid
pace. The distributed collection of data has an impor-
tant role as a rich source for testing new algorithms
for pattern recognition, and it also serves as an impor-
tant motivation for their development, as it presents
important challenges to the direct application of existing
algorithms. As in other domains, to properly employ
machine learning models to these data, it is imperative
that the researcher understands their potential and lim-
itations. The goal of this article is to review certain as-
pects of gene expression microarray measurements,
describe common analytical approaches, and familiarize
machine learning researchers with data generated by
these technologies.
1.2. Measuring gene expression
Until about a decade ago, the ability to identify and
analyze gene expression patterns has been technically
limited to a handful of genes per study. These traditional
methods include Northern blot and real-time PCR [5–8],
which, although fruitful and still in use for biological
validation experiments, have limitations in terms of
the number of gene expression patterns that can be ana-
lyzed in practice. This limitation has been overcome by
the development of several high-throughput technolo-
gies that allow more comprehensive coverage of genes,
although the measurement for each gene is usually lessaccurate than that resulting from low-throughput tech-
nologies. Some of the methods include diﬀerential dis-
play [9], serial analysis of gene expression (SAGE)
[10], and massive parallel signature sequencing (MPSS)
[11]. Other high-throughput methods, though still in
their infancy, can measure protein expression levels:
protein microarrays [12], and mass spectrometric analy-
sis [13]. The goal of DNA microarray technologies is to
measure the level of expression for large sets of genes, in
a global fashion. Although less precise than traditional
low-throughput methods, the information gained from
measuring the expression of thousands of genes simulta-
neously is considered signiﬁcant, particularly in explor-
atory phases of research. These technologies are based
on the measurement of messenger RNA (mRNA),
which is described in the context of its biological role
in Section 2. Some common issues in measuring gene
expression are pervasive across these techniques. For
example, it is not the case that the amount of mRNA
produced is always directly proportional to a known
function that is important in disease processes such as
translation into protein or regulation of another gene
[13]. However, the analyses of gene expression patterns
usually equate the amount of mRNA detected for a cer-
tain gene with its functional status.
There are two common microarray platforms for
investigating gene expression: complementary DNA
(cDNA) and oligonucleotide microarrays [14,15]. They
diﬀer in experimental protocols, lengths of probes, num-
ber of tissues measured per array thus implying chal-
lenges in the integration and comparison of data sets
from diﬀerent platforms [16]. Once issues with standard-
ization are resolved and new algorithms for their
analyses are developed, the range of applications of
microarrays will be potentially vast. They have been used
to study expression proﬁles of genes in areas of develop-
ment [17], the study of progression of a disease [18], sur-
vival [19], and response to various drug compounds [20].2. The biology behind gene expression microarray mea-
surements
Genomics is a broad category describing the develop-
ment and application of genetic information that has the
potential to lead to qualitative changes in the way in
which biomedical research is conducted in terms of diag-
nostics, risk assessment, therapeutics, and health care
outcome. The post- era has brought with it the promise
of change in the way basic experiments are conducted,
enabling biomedical researchers to examine biological
systems more comprehensively. Since the inception of
the human genome project (HPG) about a decade ago,
the 3.2 billion base pairs that make up the genome have
been sequenced to near perfection. The human genome
is believed to have between 30,000 and 40,000 genes
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assembly of proteins or regulation of other regions) [21],
each composed of hundreds to thousands of nucleotides
of four types: adenine (A), cytosine (C), thymine (T),
and guanine (G). The sequence information of our gen-Fig. 1. Transcription of DNA to mRNA and translation of mRNA to prote
DNA sequences, through mRNA that carries the genetic information (trans
(translation).
Fig. 2. Overview of a microarray experiment: procedure used in gene express
extraction from a tissue biopsy and quality control of the samples is follow
acquisition, and analysis. Biological veriﬁcation of the results can be performome serves as the basis for development of DNA micro-
arrays. However, knowledge of the sequence of
nucleotides in a gene does not directly lead to knowledge
regarding the level of expression of that gene (i.e.,
whether the gene is up-, down-, or neutrally regulated)in. Activities of the cell are controlled by instructions contained in the
cription) from the cell to the cytoplasm, where proteins are produced
ion proﬁling for target identiﬁcation and biological validation. mRNA
ed by labeling of a probe(s), hybridization onto a microarray, data
ed using a variety of approaches, such as immunohistochemistry.
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tion. Although all cells in the body possess the same
DNA, gene expression varies according to developmen-
tal stage, tissue, age, and environmental conditions. In
the study of health and disease, the goal of microarray
analysis is to characterize certain gene expression ‘‘pro-
ﬁles’’ in which the levels of expression of particular sets
of genes are highly associated.
Gene expression is an intermediate step before the
assembly of proteins from their building blocks, the ami-
no acids. When a gene is expressed, messenger RNA
(mRNA) is produced (‘‘transcribed’’) from the genes
DNA sequence, and it serves as a template to guide
the synthesis of a protein, allowing particular amino
acids to be systematically incorporated into a protein
(Fig. 1). The mRNA transcript is a complement of a cor-
responding part of the DNA coding region. The purpose
of a gene expression microarray is to measure how much
mRNA corresponding to a particular gene is present in
the cell(s) or tissue of interest.
In general, a microarray (or chip) is composed of
thousands of DNA sequences (probes), corresponding
to segments of genes that are placed in speciﬁc arrange-
ment, typically on a glass slide or a silicon microchip.
The DNA sequences can be short, as in the case of oli-
gonucleotide arrays, or long, as in the case of cDNA ar-
rays. The principle behind microarrays is that
complementary sequences will bind to each other under
the proper conditions, whereas non-complimentary
sequences will not bind. For example, if the DNA
sequence on an array is 10 nucleotides long, TACCGAA
CTG, the sequence ATGGCTTGAC will ‘‘hybridize’’ to
the probe (A nucleotides complement T and C nucle-
otides complement G). Probes are designed to be spe-
ciﬁc to a gene. On a microarray, many thousands of
spots are placed onto a grid, each spot containing the
DNA sequence from a particular gene. When a sample
of interest contains many copies of mRNA, many bind-
ings can take place, indicating a gene from which the
mRNA transcribed is highly expressed.
The steps involved in common gene expression
microarray studies are depicted in Fig. 2. The experi-
ments begin with the collection of samples of a certain
tissue (or cell) of interest, and the extraction of mRNA
from these samples. Since mRNA can be easily de-
graded, special attention is required for the collection,
preparation, and storage of these samples. A quality
control step is essential before conducting an experi-
ment, such as running the mRNA samples on an aga-
rose gel. Since mRNA is inherently unstable, cDNA,
which is more stable and easier to work with, is pro-
duced in the laboratory from the mRNA, and represents
an equivalent sequence of nucleotides.1 This cDNA is1 cDNA derived from the specimens can be used for both cDNA
and oligonucleotide arrays.labeled with a ﬂuorescent dye and will hybridize (i.e.,
bind speciﬁcally with pre-determined sequences of nucle-
otides representative of a certain gene) to sequences that
are immobilized on the microarray. Quantifying the
ﬂuorescence signal intensity allows one to assess the
amount of hybridization. Those sequences that do not
hybridize will be washed away leaving no signal. Images
from the ﬂuorescent probes are read by a scanner and
translated into numerical values. The mRNA abun-
dance in a cell or tissue (or corresponding cDNA that
is made from it in the laboratory) is therefore a proxy
for the measure of gene expression: when certain genes
become ‘‘expressed,’’ many copies of mRNAs corre-
sponding to those genes are produced. These copies will
hybridize with microarray probes that are complemen-
tary (Fig. 3). The major assumption is that the abun-
dance of mRNA corresponding to a certain gene is
positively correlated with the expression of a certain
gene.3. How to access the data?
Many data sets are publicly available via the internet,
additionally there are hundreds of life sciences databases
reported in the literature [22], which stresses the diﬃ-
culty to where and how to search information in a fast
and eﬃcient manner [23]. Fig. 4 illustrates common for-
mats for publication of gene expression data from
microarrays. The published data usually constitute a
transformed version of the initial data set, and has usu-
ally been subject to pre-processing in the form of ﬁlter-
ing and normalization. Gene expression data derived
from microarrays can be obtained in web supplements
to journal publications or in public repositories. There
are a number of eﬀorts well underway to create public
gene expression databases. Two leading contenders that
have become the de-facto public databases for arrays are
Array Express at the European Bioinformatics Institute
(http://www.ebi.ac.uk/arrayexpress/), and the NCBIs
Gene Expression Omnibus GEO (http://www.ncbi.nlm.
nih.gov/geo/). Other important sources of microarray
data are the Stanford Microarray Database (http://
genome-www5.stanford.edu/), the DukeMicroarray Cen-
ter database (http://mgm.duke.edu/genome/dna_micro/
work/), and the Whitehead Institute Cancer Genom-
ics database (http://www.broad.mit.edu/cgi-bin/cancer/
datasets.cgi). In this context, it is important that this
information be archived in standardized fashion, which
is usually not the case for many journal supplements and
individual laboratory web sites. This eﬀort towards stan-
dardization has been initiated by the Microarray Gene
Expression Data (MGED www.mged.org) Society,
which has taken the initiative to develop and enforce
guidelines, formats and tools for submission of micro-
array data [24]. This allows researchers to share com-
Fig. 4. Illustration of diﬀerent raw data formats that were generated using diﬀerent extraction software after scanning, GenePix 4.0 for cDNAdata and
MAS 5.0 for Aﬀymetrix GeneChips. In cDNA data (two-dye, two-sample experiment), there are diﬀerent attributes that are used in the analyses;
intensity, background data for both dyes, and ﬂags for bad spots. In Aﬀymetrix data (one-dye, one sample), one can use the detection calls (absent,
marginal, and, present) and signal intensity for analyses.
Fig. 3. Microarrays contain thousands of probes that can vary in length (from 25 to over 1000bp) that are aﬃxed onto a solid surface. Microarray
experiments can be broken down to two groups based on their labeling bias, one-dye or two-dye experiments. Essentially in two sample experiments,
two samples are labeled either with a Cy3-dye or a Cy5-dye, producing a ratio unit measurement, whereas in a single-dye experiment, an absolute unit
of measurement is generated.
Fig. 5. (A) Representative example of gene speciﬁc PCR for microarray validation. PCR using primers speciﬁc for gene pax6 or chx10 was performed
on the cDNA preparations from E15 single retinal progenitor cells (lanes 1, 3, 5, and 7) or controls (lanes 2, 4, 6, and 8). (B) Representative examples of
in situ hybridizations for microarray validation. E15 retinas were either sectioned (B) or dissociated (C) and hybridized with a probe for gene Fgf15.
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experiments. MGED is an international organization
of scientists involved with gene expression proﬁles. Their
primary contributions are proposed standards for publi-
cation and data communication. MGED proposed min-
imum information about a microarray experiment
(MIAME) as a potential publication standard [25].
MAGE-ML is a proposed mark-up language for micro-
array experiments (http://www.mged.org/Workgroups/
MAGE/mage-ml.html).
A typical experiment has thousands of genes, few
samples, and minimal information other than gene
expression measurements. Some experiments link clini-
cal data to the information about gene expression in
the arrays, but this information is usually minimal
(e.g., survival days, age, and gender) and rarely pub-
lished, so it is not appropriate to attempt to utilize
the resulting models in the clinical setting. Not all avail-
able microarray data sets are appropriate for machine
learning research. Many experiments contain too few
arrays. Although each array contains information on
thousands of genes, it may not make sense to try to ex-
tract generalizable patterns from this type of experi-
ments. It is important to emphasize that, for most
machine learning applications, the unit of analysis is
not the gene, but rather the array (tissue sample). Just
as it does not make sense to establish phenotypic pat-
terns of disease (e.g., deﬁne the proﬁle of laboratory
tests that is related to diabetes) by analyzing the results
for one or two patients with disease and a couple of
healthy subjects, it does not make sense to establish
gene proﬁles by examining a few arrays. The sample
size has to be suﬃciently large for the construction of
generalizable models. Since accruing subjects or obtain-
ing specimens and performing measurements in micro-
arrays is still costly, there is an important limitation
in terms of which data sets can be eﬀectively used for
machine learning research.
Table 1 lists some data sets that have been previously
used in machine learning experiments. The extent to
which patterns can be learned and generalized from
these data sets is variable. The list contains data from
experiments with a relatively large number of cases that
can be used by machine learning researchers who would
like to get familiar with this type of data. ConsiderableTable 1
List of some microarray data sets used in machine learning research
Specimen No. of samples No. of ge
Adenocarcinomas 279 9376 com
Breast cancer 117 25,000
Drosophila melanogaster 66 4028
Prostate cancer 52 12,600
CNS embryonal tumors 99 6817
Primary tumors 144 16,063
Small round blue cell tumors 63 6567
Lung carcinomas 186 12,600pre-processing of these data sets is necessary before they
can be used for machine learning research, although pre-
processed versions of these data may often be obtained
upon request.4. Common modeling techniques and computational
challenges
The advantage of DNA microarrays is that they
allow the study of multiple transcriptional events in a
single chip, which corresponds to one experiment.
Therefore, the values for thousands of variables (genes)
can be simultaneously measured for a particular biolog-
ical sample. The cost of processing each sample,
however, is relatively high, so there are few cases (bio-
logical samples) per study. Signiﬁcant steps towards
increasing the reliability of measurements have been ta-
ken in the past few years. The main challenge in micro-
array studies resides in proper study design and eﬃcient
and realistic interpretation of the information. There are
several issues that need to be considered for a study,
such as: (i) the type of DNA microarray platform
selected for the experiment (each having diﬀerent
protocols, sensitivities, and speciﬁcities); (ii) mRNA
preparation (such as type of specimen, availability, het-
erogeneity); and (iii) data analysis (pre-processing, unsu-
pervised, and supervised learning). Since each step of a
microarray experiment is subject to diﬀerent sources of
variability, there is large variance in microarray mea-
surements; it is common practice to have duplicate or
triplicate arrays for the same sample [26]. A major hur-
dle is the extraction of meaningful information from the
large amount of expression data generated from micro-
array studies (large m, small n problem, where m is the
number of variables or gene measurements, and n is
the number of observations from which those measure-
ments are obtained). Other issues that should not be
overlooked when analyzing microarray data are outliers
and missing values.
4.1. Pre-processing
In a typical microarray analysis, the initial step is pre-
processing of the data, which includes ﬁltering andnes Platform Author
mon Aﬀymetrix, cDNA Ramaswamy et al. [63]
cDNA vant Veer et al. [64]
cDNA Arbeitman et al. [65]
Aﬀymetrix Singh et al. [66]
Aﬀymetrix Pomeroy et al. [67]
Aﬀymetrix Ramaswamy et al. [35]
cDNA Khan et al. [3]
Aﬀymetrix Bhattacharjee et al. [21]
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number of genes for further data analysis. Measure-
ments of genes that represent many copies per cell (high
abundance) tend to be more reliable and more consistent
than measurements that represent genes with low abun-
dance regardless of the microarray technology utilized.
A natural explanation may be that there is inherent
noise in the hybridization and/or signal detection pro-
cesses, which for weak signals of low-abundant tran-
scripts results in lower signal to noise ratio compared
to the stronger signals of high-abundant transcripts.
This eﬀect is seen in one-dye (one sample) platforms,
but in two-dye platforms, from which ratios are calcu-
lated, these eﬀects are ampliﬁed and the ratio estimates
are confounded by uncertainty of two numbers rather
than by only one. As a result, it has become common
practice to ﬁlter out weak signals, for which it is as-
sumed that the signal-to-noise ratio is too low for the
data to be useful. This ﬁltering process includes the iden-
tiﬁcation and removal of array elements prior to further
analyses. It is important to investigate the amount of
true signal that is being ﬁltered out in this ﬁltering pro-
cess. Future research on microarray analysis should for-
mally address this issue. Some important transcription
factors exhibit low but diﬀerentiable levels of expression
under diﬀerent circumstances. This type of information
may be lost in the ﬁltering process.
After ﬁltering out unreliable observations, many
sources of systematic and experimental variation that
confound the observed gene expression levels still re-
main in the microarray experiments. Normalization is
a method to adjust the means or variances of the varia-
tion in the measured expression intensities. This im-
proves the monitoring of biological diﬀerences and
allows the comparison of expression levels across multi-
ple experiments. A review of normalization procedures
is beyond the scope of this article. Readers should refer
to [21,27–29] for details.
4.2. Statistical and machine learning models
In addition to coding well-known algorithms for data
pre-processing and evaluation, new algorithms and ap-
proaches for clustering, classiﬁcation, and evaluation
are needed. Various mathematical and statistical tools
have been developed to cluster genes by integrating
them with biological pathways or to perform class pre-
dictions that identify expression patterns that correlate
with phenotypic characteristics. The development of
new machine learning models to extract knowledge
(such as relationships between genes and disease and
among genes themselves) [30] from large data sets is very
important in this stage of genomic research. There is a
need to expand the set of models available to research-
ers, allow them to select the adequate models for their
data, investigate new ways to determine the importanceof individual variables and individual observations, and
make it possible to combine models.
Diﬀerential expression of genes under various condi-
tions or time points is usually the focus of the analysis.
This type of analysis can be done using one gene at a
time (univariate) or several genes at a time (multivari-
ate). Univariate analysis of gene expression data sets is
sometimes useful and has been utilized in several studies.
Examples of univariate analyses include the inspection
of fold-diﬀerences, calculation of p values using methods
analogous to t tests, and ANOVA [31–33]. As our
understanding of biology increases, it becomes evident
that there are many instances in which a combination
of genes, rather than one gene in isolation, may contrib-
ute to the biological process under investigation. There-
fore, it is critical that we analyze gene expression data
using a multivariate approach, even though univariate
analysis may still play a role in ﬁltering genes in the
pre-processing phase [34].
Unsupervised learning is done in order to investigate
which genes behave in a similar manner or which genes
exhibit high covariance. This was a very popular tech-
nique when the number of cases studied was small (for
example, when tissues at a certain developmental stage
or condition were pooled together to be analyzed by a
single array). There are several examples in the literature
on the use of hierarchical clustering, self-organizing
maps, multidimensional scaling, and several clustering
algorithms in gene expression data [35–38]. This explor-
atory analysis technique is a good ﬁrst step towards
identifying clusters of related genes, but its use for iden-
tifying disease progression markers or clustering cases
into categories of interest is limited. Unsupervised tech-
niques are in many cases inappropriately utilized as a
replacement to supervised techniques (e.g., in studies
in which researchers want to classify cases into known
categories such as benign versus malignant). In this con-
text, the analysis cannot guarantee that the clusters of
interest will result from the data, although this may in-
deed happen. It is worth noticing that distances and
other non-weighted measures of association between ob-
jects can be misleading in the task of forming clusters of
interest. This is especially true when the sample size is
small.
As larger experiments involving microarrays are
being published, there is an increasing number of publi-
cations reporting the analysis of microarray data using
supervised classiﬁcation algorithms, such as support
vector machines [39], artiﬁcial neural networks [3],
regression [40], and various types of rule-induction algo-
rithms [41]. Tools to support classiﬁcation algorithms
that work with a high ratio of variables/cases are still
rare. The problem with using conventional statistical
multivariate techniques, such as discriminant analysis
and regression, is that they do not work when the num-
ber of variables exceeds the number of cases, which so
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Therefore, techniques for reducing the number of vari-
ables that are directly used in the models have been uti-
lized. Some of these, such as principal components
analysis, are unsupervised in nature, and therefore do
not guarantee that the reduction is done in a way that
optimizes the predictive model. Furthermore, they
merely ‘‘compress’’ the variables and the resulting com-
ponents do not have any particular meaning. Utilizing
partial least squares partially resolves the ﬁrst issue (as
it is a supervised variable ‘‘compression’’ technique),
but still does not allow direct identiﬁcation of important
variables (genes), which is the goal of many analyses. In
order to do this, variable selection algorithms are
needed.
Identifying which genes contribute the most for the
estimate in a particular predictive model can be done
via variable selection methods. A number of variable
selection techniques exist and some have been used in
the bioinformatics literature. Some algorithms, such as
forward stepwise selection of variables, utilize a gradient
descent approach, with or without a stochastic compo-
nent, making them more or less susceptible for stopping
after reaching non-optimal solutions (i.e., local minima).
Some authors indicate that this greedy approach can
perform as well as more complex ones in a number of
data sets [42]. Other algorithms, such as those based
on evolutionary techniques (such as genetic algorithms)
can rarely be used without a signiﬁcant pre-selection of
variables, given time constraints. Discovering new para-
digms for variable selection in predictive models is crit-
ical for deﬁning few genetic markers for disease
progression in models derived from microarray data.
Hence the increasing number of research articles that
deal with variable selection for microarray data analysis
[31].
Variable selection techniques can be divided into
those that perform the selection using a purely univari-
ate approach, and those that are multivariate. Purely
univariate techniques have been used in the bioinformat-
ics literature [43,44], but multivariate techniques are just
beginning to be investigated. For example, the Good-
man–Kruskal association index was used in the context
of partitions to select biomarkers for malignancy in [45].
New methods for variable selection are needed. Pub-
lished work in this area includes variations of genetic
algorithms to promote en bloc selection of variables,
which were shown to result in variable selections that
outperform classic sequential forward, backward, or
stepwise selection procedures [46]. In microarray analy-
sis, data sets consist of thousands of variables, and often
no more than dozens of cases. Related to the variable
selection problem is that of overﬁtting, which has been
investigated in the context of remedial strategies such
as bootstrapping [47–49], cross-validation (including
jackknife) [50,51], shrinkage, and other methods [52].Some machine learning researchers overlook the
importance of conducting proper evaluation of models,
especially the issue of overﬁtting. The ‘‘curse of dimen-
sionality’’ is well illustrated in microarray data, and
researchers who are testing new algorithms may get a
false impression that their models will generalize well
to new data just because they can perfectly ﬁt the train-
ing data.
As in similar problems, to attenuate the problem of
overﬁtting, without increasing the cost of the experi-
ment, two approaches can be potentially useful:
1. Resampling of training cases, such that test cases are
not used for building a model. No new information is
added with this strategy, but a better assessment of
the generalizability of the model is achieved this
way. Techniques such as cross-validation and boot-
strap can be used and are discussed in [53]. Given that
the number of cases in a particular category may be
small, it is advisable to create cross-validation parti-
tions by randomly sampling cases from each category
in a way that the proportion of cases remains the
same in each partition. A large number of bootstrap
samples and related models can be generated by ran-
domly sampling the arrays with replacement. Non-
sampled cases can be used for testing of each model.
2. Decrease in the number of variables. Variable selec-
tion methods are used for this purpose, as discussed
before.
A topic of ultimate importance for the mathematical
validation of results is the choice of evaluation indices.
Unsupervised learning models produce results that are
diﬃcult to interpret and evaluate objectively. For clus-
tering models, the most acceptable strategy is to devel-
op clusters according to several diﬀerent objective
functions (e.g., maximization of the inter-cluster
Euclidean distances over intra-cluster distances) and
evaluate the resulting clusters according to [1] measures
of cluster concordance, and [2] known properties of the
objects (e.g., functional classiﬁcation) [54,55]. For clas-
siﬁcation problems, regions under the ROC curve
[56,57] and standard conﬁdence intervals can be used
to assess discrimination ability of the models even in
multi-categorical cases [58]. When new supervised
learning algorithms are being tested, it is important
to compare their results with those deriving from estab-
lished methodologies such as regression. When diﬀerent
models are compared on the same data, adjustments to
the conﬁdence interval need to be made to account for
the correlation of results. This results in narrower con-
ﬁdence intervals and improved potential to detect dif-
ferences in performance. Calculating conﬁdence
intervals without adjusting for correlations is more
conservative and hence less likely to demonstrate
diﬀerences.
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After a comprehensive data analysis, the list or clus-
ter of genes that have been identiﬁed as linked to a par-
ticular condition or developmental process requires
further investigation to determine its biological signiﬁ-
cance. It is imperative for biomedical investigators to as-
sess the false-positive rate and conduct independent
biological validations to conﬁrm the results generated
computationally. The most commonly used techniques
to verify gene expression data include Northern blots
and PCR-based approaches (both quantitative and
semi-quantitative) (Fig. 5A). The advantages of these
methods are twofold. First, these methods can be per-
formed quantitatively. Secondly, Northern blot and
PCR can be used to screen through a large number of
candidates relatively rapidly. Other methods of valida-
tion include in situ hybridization (Fig. 5B) and immuno-
histochemistry. These approaches oﬀer the extra beneﬁt
of showing exactly where in a particular tissue the
candidate genes are expressed [59,60]. However, tradi-
tionally these methods are neither quantitative nor
high-throughput. Recently, however, several studies
have demonstrated that in situ hybridizations can be
used to screen a large number of candidate genes [17]
and, in some cases, this can be performed in a quantita-
tive manner (Fig. 5C) [17,61].
A candidate gene-by-gene validation approach,
which involves experiments with a few potentially
important genes, is a viable and successful method.
This approach is not appropriate to provide a more
comprehensive understanding of the larger process of
biological networks and pathways. Often, the same sig-
naling molecules or transcription factors are commonly
expressed in multiple tissues or stages. Studies suggest
that the same gene can play distinct developmental
roles in these circumstances, being signiﬁcant in one
tissue but unessential or redundant in another. More-
over, the function of any gene is often context depen-
dent. For example, the ability of a signaling molecule
to activate a speciﬁc diﬀerentiation pathway largely de-
pends on the target cells competence to receive and
interpret the signal and its ability to utilize an existing
signal transduction system that, in the presence of
appropriate co-factors and nuclear transport assem-
blage, will activate or down-regulate downstream
genes. In short, the functional importance of any gene
depends on the presence or absence of products of
many other genes. If, as some studies suggest, binary
and more complex combinations of signaling molecules
are needed to control certain biological processes, then
this problem is magniﬁed many-fold. Here again, a lar-
ger scale genomic approach coupled with sophisticated
analyses could be potentially useful for elucidating the
molecular network behind particular biological phe-
nomena. This can be illustrated by using tools thatintegrate both microarray results and resources from
private and public databases to generated networks/
pathways that can assist our understanding in how
these genes and/or proteins interact with each other
as seen in [62].6. Conclusion
In conclusion, new sources of data such as those de-
rived from gene expression microarrays oﬀer new chal-
lenges for the development and evaluation of statistical
and machine learning algorithms. The large number of
variables per observation can give researchers a false
impression of having ‘‘lots of data’’ that are useful for
machine learning research. In fact, most of the current
data sets contain few observations, hence the main chal-
lenge is to select a small set of variables that are represen-
tative of the data, and build models that are potentially
generalizable to a new set of cases. Careful internal and
biological validation allows quantitative assessment of
the potential for generalization of the machine learning
models derived from the data. It is important to note that
generalization will depend on a series of other issues as
well, such as: microarray platform, reference sample,
manipulation of the samples, normalization procedures,
and intrinsic noise in the measurements.Acknowledgments
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